NCT03059069View on ClinicalTrials.gov

The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Type2 Diabetes With Depressive Mood
Interventions
DRUG

Chonline Alphoscerate

Patients treated with Chonline Alphoscerate as add on therapy to their medication

DRUG

Placebo Oral Tablet

Patients maintain their medication with either Gliatamin or placebo for 6 months.

Trial Locations (1)

03722

RECRUITING

Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER